A third patient who received an experimental Audentes gene therapy for a rare neuromuscular disorder has died, a disclosure that comes two months after the deaths of two patients led the FDA to place a clinical hold on the study.
San Francisco-based Audentes, a subsidiary of Japanese pharmaceutical company Astellas Pharma, said Friday that early findings indicate that gastrointestinal bleeding was the cause of the most recent death. That patient received the high dose of the gene therapy, the same dose given to the patients whose deaths were disclosed in June.
The Audentes gene therapy, dubbed AT132, is in development as… Read more »
UNDERWRITERS AND PARTNERS